Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-26-062780
Filing Date
2026-05-15
Accepted
2026-05-15 17:06:30
Documents
85
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q hypd-20260331x10q.htm   iXBRL 10-Q 1853855
2 EX-31.1 hypd-20260331xex31d1.htm EX-31.1 12098
3 EX-31.2 hypd-20260331xex31d2.htm EX-31.2 12110
4 EX-32.1 hypd-20260331xex32d1.htm EX-32.1 5498
5 EX-32.2 hypd-20260331xex32d2.htm EX-32.2 5552
  Complete submission text file 0001104659-26-062780.txt   9774530

Data Files

Seq Description Document Type Size
6 EX-101.SCH hypd-20260331.xsd EX-101.SCH 89919
7 EX-101.CAL hypd-20260331_cal.xml EX-101.CAL 56823
8 EX-101.DEF hypd-20260331_def.xml EX-101.DEF 329032
9 EX-101.LAB hypd-20260331_lab.xml EX-101.LAB 518202
10 EX-101.PRE hypd-20260331_pre.xml EX-101.PRE 502015
89 EXTRACTED XBRL INSTANCE DOCUMENT hypd-20260331x10q_htm.xml XML 1932651
Mailing Address 295 MADISON AVENUE SUITE 2400 NEW YORK NY 10017
Business Address 295 MADISON AVENUE SUITE 2400 NEW YORK NY 10017 833-393-6684
HYPERION DEFI, INC. (Filer) CIK: 0001682639 (see all company filings)

EIN.: 471178401 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38365 | Film No.: 26989621
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)